GlassScriptPhysician profile
Matthieu D Myers
NPI 1588846877
$781.56
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $252 · 2023: $96.54 · 2024: $19.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $170.69 | 2021-2022 | |
| Depuy Synthes Sales INC. | $147.81 | 2021-2022 | |
| Redhill Biopharma INC. | $77.39 | 2021-2022 | |
| Smith+Nephew, INC. | $65.00 | 2023 | Real Intelligence, Grafix, Stravix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.37 | 2021 | |
| Djo, LLC | $43.49 | 2022 | |
| Ferring Pharmaceuticals INC. | $37.74 | 2021-2022 | |
| Pacira Therapeutics, INC. | $35.66 | 2021 | |
| Bioventus LLC | $29.57 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $20.79 | 2022 | |
| Molnlycke Health Care US, LLC | $19.34 | 2024 | Mepilex Border Post-Op Ag, Avance |
| Next Science LLC | $16.22 | 2023 | Xperience, Surgx, Blastx |
| Heron Therapeutics, INC. | $15.32 | 2023 | Zynrelef |
| Eisai INC. | $14.29 | 2021 | |
| Trevena, INC. | $13.26 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $12.99 | 2021 | |
| Abbott Laboratories | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthieu Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.